Bulletin # 1027

May 21, 2020

NB Drug Plans Formulary Update

This update to the New Brunswick Drug Plans Formulary is effective May 21, 2020.

Included in this bulletin:

- Special Authorization Benefit Additions
- Drugs Reviewed and Not Listed

If you have any questions, please contact our office at 1-800-332-3691.

The Formulary Updates are available online: http://www.gnb.ca/0212/BenefitUpdates-e.asp. To unsubscribe from the NB Drug Plans email announcements, please send a message to info@nbdrugs-medicamentsnb.ca.

Special Authorization Benefit Additions

Product	Strength	DIN	MFR	Plans	Cost Base
Buprenorphine (Sublocade™)	100 mg / 0.5 mL prefilled syringe 300 mg / 1.5 mL prefilled syringe	02483084 02483092	IUK	(SA)	MLP

For the treatment of patients with opioid use disorder who have been stabilized on a dose of 8 mg to 24 mg per day of sublingual buprenorphine for a minimum of seven days.

Clinical Note:

- The patient must be under the care of a prescriber certified under the Sublocade Certification Program.

Claim Note:

- Approvals will be for one prefilled syringe per month. A minimum of 26 days is required between claims.

Doravirine (Pifeltro®)	100 mg tablet	02481545	FRS	(SA)	MLP

For use in combination with other antiretrovirals in adult patients with HIV-1 infection, who have no known mutations associated with resistance to doravirine.

Claim Note:

- Prescriptions written for beneficiaries of Plan U by infectious disease specialists and medical microbiologists who are licensed by the College of Physicians and Surgeons of New Brunswick, do not require special authorization.

Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate (Delstrigo®)	100 mg / 300 mg / 300 mg tablet	02482592	FRS	(SA)	MLP

For the treatment of adult patients with HIV-1 infection with no known mutations associated with resistance to the individual components of Delstrigo.

Claim Note:

- Prescriptions written for beneficiaries of Plan U by infectious disease specialists and medical microbiologists who are licensed by the College of Physicians and Surgeons of New Brunswick, do not require special authorization.

Lixisenatide (Adlyxine™)	0.05 mg/mL prefilled pen 0.1 mg/mL prefilled pen	02464276 02464284	SAV	(SA)	MLP

For the treatment of type 2 diabetes as a:

- second drug added to basal insulin for patients who have inadequate glycemic control on basal insulin; or
- third drug added to basal insulin and metformin for patients who have inadequate glycemic control on metformin and basal insulin.

Drugs Reviewed and Not Listed

Requests for special authorization of the following products will not be considered.

Product	Strength	DIN	MFR	Indication
Abemaciclib (Verzenio™)	50 mg tablet	02487098	LIL	For patients with hormone receptor positive, HER2-negative advanced or metastatic breast cancer when used in combination with a non-steroidal aromatase inhibitor as initial endocrine-based therapy or in combination with fulvestrant following disease progression on endocrine therapy.
	100 mg tablet	02487101		
	150 mg tablet	02487128		
	200 mg tablet	02487136		
Dacomitinib (Vizimpro™)	15 mg tablet	02486024	PFI	As first-line treatment for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer with confirmed EGFR (exon 19 deletion or exon 21 L858R substitution) mutations.
	30 mg tablet	02486032		
	45 mg tablet	02486040		
Lorlatinib (Lorbrena™)	25 mg tablet	02485966	PFI	For adult patients with ALK-positive metastatic non-small cell lung cancer who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.
	100 mg tablet	02485974		
Methylphenidate hydrochloride (Foquest®)	25 mg CR capsule	02470292	PFR	For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients ≥18 years of age.
	35 mg CR capsule	02470306		
	45 mg CR capsule	02470314		
	55 mg CR capsule	02470322		
	70 mg CR capsule	02470330		
	85 mg CR capsule	02470349		
	100 mg CR capsule	02470357		
Neratinib (Nerlynx®)	40 mg tablet	02490536	KNI	For patients with hormone receptor positive, HER2-positive breast cancer who have completed trastuzumab-based therapy within the past 12 months.